Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

IsoCross: Cross-species comparison of isoflavone intervention on estrogen sensitivity, metabolism, epigenetics and carcinogenesis

IsoCross team during the kickoff meeting at the MRI in Karlsruhe
© P. Diel

There is an ongoing controversial debate whether phytoestrogenic isoflavones (IF) found for example in soy products have breast cancer preventive activity, or whether exposure to isoflavones may even increase the breast cancer risk.

The aim of the DFG-funded IsoCross initiative is to characterise molecular mechanisms which determine whether the exposure towards specific IF metabolite profiles may be adverse or protective with respect to the risk to develop breast cancer, and to correlate them with levels of IF/E2 metabolites, taking into account the influence of dietary fat consumption and body fatness.

The DKFZ subproject of IsoCross will characterize genome-wide epigentic changes in mammary gland tissue after IF expoure for specific time intervals during development (in utero, perinatal, (pre)pubertal, or life-long) and investigate functional consequences for tisuse-specific estrogen sensitivity and mammary carcinogenesis in rat models and human pilot intervention studies.

Our hypothesis is that early molecular changes in developing breast tissue will determine breast cancer susceptibility later in life. The knowledge acquired will be crucial for the evaluation of potential prevention strategies.

to top
powered by webEdition CMS